Joris Wilms is COO & VP at Y-mAbs Therapeutics, Inc. (YMAB). They have made 1 open-market trade across 1 company since 2024, most recently 2025-09-16.
CIK 0001753231
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| YMAB | 52,100 | $449K |
Shares reported on the most recent Form 4, priced at the 2025-01-22 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| YMAB | SELL | 2024-08-26 | 2024-08-27 | $14.69 | $73K | -10.8% | -14.5% | -29.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.